Re: COVID-19 - Part 2
You're still pimping HCQ? Even after the doctor was exposed as a complete fraud and the studies have been torn apart by the academic community? Even after studies that were larger and designed better have shown zero evidence it helps? Still?
LOL
My post regarding an RCT that is currently being conducted under the leadership of a colleague, Dr. Dave Boulware, is "pimping" HCQ?

I don't have any axe to grind here, but apparently you do.
If you want to falsely accuse US healthcare professionals as well as those around the globe (India, Germany, France, etc.) who are currently administering HCQ/AZ to CoV-19 patients with measured success of "pimping" that's entirely up to you. Go ahead and embarrass yourself.
It's noteworthy that Kansas City area physicians. as well as others in several states are continuing to treat CoV-19 patients with HCQ/AZ and are showing marked improvement in the reduction of the viral load. Major medical centers including the University of Washington and Mass General have added HCQ to treatment options. Other state pharmacy boards including Texas, Louisiana, Ohio and North Carolina have approved its use under physician care by prescription only which prevents individuals from misusing the drug by self-medicating.
Yesterday the FDA and The Department of Health and Human Services (HHS) approved HCQ products to be distributed and prescribed by doctors through the Strategic National Stockpile to hospitalized teen and adult patients with CoV-19 as appropriate.
HHS said Germany’s Sandoz has already given 30 million doses of HCQ to the Strategic National Stockpile, and Bayer has donated a million doses. Pfizer has announced positive data for the use HCQ/AZ in an RCT recently completed in Marseille, France (see below).
I'd like to see the evidence to confirm your accusation that Dr. Didier Raoult MD. PhD. is a "fraud". Arguably, his previous small study raised some concerns on the research design side. But Dr. Raoult was officially a member of the first scientific council set up by French President Macron to advise him on the CoV-19 pandemic. He's definitely NOT a fraud.
In fact, Dr. Raoult and a collaborative team of 28 microbiologists, physicians, biostatisticians, and pharmacologists in Marseille just completed and published the
largest RCT to date last week on March 27 involving 80 CoV-19 patients who were treated with HCQ/AZ. The study was conducted at the University Hospital Institute Méditerranée Infection in Marseille, France and financially supported by the French National Research Agency.
The median age was 52 years (range 20 to 86) with nearly 1:1 male/female. The primary therapeutic objective was to treat patients who have moderate or severe infections at an early enough stage to avoid progression to a serious and irreversible condition. The elimination of viral carriage in the human reservoir of the virus was recognized in the study as a priority.
57.5% of the patients had at least one chronic condition known to be a risk factor for the severe form of CoV-19 with hypertension, diabetes and chronic respiratory disease being the most frequent. The mean Polymerase chain reaction (PCR) (a method used to copy and amplify specific DNA samples for detailed analysis) CT value was 23.4. A PCR CT value < 34 means the patient has tested positive for CoV-19.
A rapid fall of nasopharyngeal viral load tested by PCR was noted, with 83% negative at Day 7, and 93% at Day 8. The number of patients presumably contagious (with a PCR CT value <34) steadily decreased overtime and reached zero on Day 12.
The team concluded that the rapid negativation of viral cultures from patients’ respiratory samples under treatment with HCQ/AZ showed the efficacy of the HCQ/AZ dyad. Moreover, the rapid decrease in the viral RNA load also suggests the effectiveness of the treatment in the early impairment of contagiousness.
<img class="alignnone wp-image-15217 size-large" src="https://blogs.sciencemag.org/pipeline/wp-content/uploads/sites/2/2020/03/HCQ-chart-1024x775.jpeg" alt="" width="600" height="400"
Recent Marseille, France study